ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

EULAR 2016

European League Against Rheumatism Annual Congress

Rheumatology Network's coverage of EULAR 2016 (June 8-11, London) includes new developments in secukinumab for AS; ultrasound-guided steriods; taking osteoarthritis more seriously and more.    (©S.Borisov/Shutterstock.com)

EULAR 2016

©SebastianKaulitzki/Shutterstock.com

EULAR 2016: Cardiovascular disease risk in rheumatoid arthritis is quite different from risk factors in the general population. Risk calculators should be different too, experts say.

@AlexanderRaths/Shutterstock.com

EULAR 2016: Patient education and compliance often take a back seat to disease management, but they need to be at the forefront of care.

©SutthaBurawonk/Shutterstock.com

EULAR 2016: Secukinumab prevents radiographic progression in 80 percent of ankylosing spondylitis patients and provides sustained improvements.

©JuanGaertner/Shutterstock.com

EULAR 2016: Inflammatory bowel disease is commonly associated with psoriasis, psoriatic arthritis and ankylosing spondylitis.

©Sheff/Shutterstock.com

EULAR 2016: A new study shows that patients with osteoarthritis may carry a greater burden of disease than patients with rheumatoid arthritis.

©SoloviovaLiudmyla/Shutterstock.com

EULAR 2016: A new study shows an association between daily exposure to air pollutants and childhood-onset systemic lupus erythematous.

©LipowskiMilan/Shutterstock.com

EULAR 2016: Ixekizumab significantly helped signs and symptoms of psoriatic arthritis in a phase 3 study reported this week.

Pages

Subscribe to EULAR 2016 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.